

Please type a plus sign (+) inside this +

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office, US DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

(Modified) PTO/SB/21 (6-98)

**TRANSMITTAL
FORM**

APR 29 2002
U.S. PATENT & TRADEMARK OFFICE
(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

09/851,586

Filing Date

May 8, 2001

First Named Inventor

Glenn L. Millhauser

Group Art Unit

1645

Examiner Name

Unassigned

Attorney Docket Number

407T-980910US

TECH CENTER 1600/2900

MAY 01 2002

COPY OF PAPERS
ORIGINALLY FILED

ENCLOSURES (check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment / Response
- After Final
- Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Small Entity Statement
- Request for Refund

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice Brief Reply Brief)
- Proprietary Information
- Status Letter
- Additional Enclosure(s) (please identify below):
- 5 References receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Tom Hunter, Reg. No. 38,498.

Quine Intellectual Property Law Group P.C.

Signature



Date

18 April 2002


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D C 20231 on this date April 19, 2002

Typed or printed name

Chianti Appling

Signature



Date

04/19/02

APR 29 2002

Thereby certifying this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents,

Washington, D.C. 20231.

On

April 29, 2002

Quine Intellectual Property Law Group, P.C.

By

Chantel Appling

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

Attorney Docket No. 407T-980910US
Client Ref. No. 1999-352-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Glenn L. Millhauser, et al.

Application No.: 09/851,586

Filed: May 8, 2001

For: METHODS AND COMPOUNDS
FOR MODULATING MELANOCORTIN
RECEPTOR LIGAND BINDING AND
ACTIVITY

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of a communication related to the results of the partial international search for corresponding International Application No. PCT/US01/15080. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Tom Hunter
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

TH:ca

Substitute for form 1449A-B PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

09/851.586

May 8, 2001

May 8, 2001

1645

1043

Unassigned

21

—
—
—

—

TECH CENTER 1600/2900

MAY 01 2002

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number			
	1	PCT	WO 99/50295	Gryphon Sciences	7 October 1999	
	2	PCT	WO 01/30808 A1	The Regents of the University of California	3 May 2001	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	3	TOTA ET AL. (1999) "Molecular Interaction of Agouti Protein and Agouti-Related Protein with Human Melanocortin Receptor", Biochemistry 38: 897-904.	
	4	BOLIN ET AL. (1999) "NMR structure of a minimized human agouti related protein prepared by total chemical synthesis", FEBS Letters 451: 125-131	
	5	HRUBY, J. ET AL. (1995) "Cyclic Lactam α -melanotropin analogues of ac Nle4-cyclo[Asp5, D-Phe, Lys10] α -melanocyte-stimulating hormone-(4-10)-NH ₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors", J. Med. Chem. 38: 3454-3461.	

Examiner
Signature

Date
Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in
last considered. Include copy of this form with next communication to applicant.